| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 |
|---|---|---|---|---|---|---|---|---|
Revenue: | ||||||||
CytoSorb sales | ||||||||
- | - | - | 8,206 | - | - | - | - | - |
Other sales | ||||||||
- | - | - | 0 | - | - | - | - | - |
Total revenue | ||||||||
24,949 | 22,503 | 15,150 | 8,206 | - | - | - | - | - |
Grant income | ||||||||
- | - | - | 1,321 | - | - | - | - | - |
Total Product Sales | ||||||||
- | - | - | - | 4,043 | 3,135 | 821 | 151 | 36 |
Grant income | ||||||||
- | - | - | - | 735 | 978 | 1,600 | 1,191 | 0 |
Other revenue | ||||||||
- | - | - | - | 11 | 9 | 0 | - | - |
Total revenue | ||||||||
- | - | - | - | 4,791 | 4,122 | 2,422 | 1,342 | 36 |
Total revenue | ||||||||
- | - | - | 9,527 | - | - | - | - | - |
Cost of revenue | ||||||||
7,363 | 7,489 | 5,518 | 3,953 | - | - | - | - | - |
Cost of revenue | ||||||||
- | - | - | - | 2,212 | 2,133 | 1,911 | 319 | 11 |
Gross margin | ||||||||
17,585 | 15,014 | 9,632 | 5,574 | 2,579 | 1,988 | 511 | 1,023 | 24 |
Other expenses: | ||||||||
Research and development | ||||||||
12,091 | 7,723 | 3,221 | 4,073 | 3,871 | 2,431 | 1,738 | 2,532 | 2,888 |
Legal, financial and other consulting | ||||||||
2,462 | 2,002 | 1,339 | 1,184 | 1,089 | 896 | 908 | 627 | 342 |
Selling, general and administrative | ||||||||
22,005 | 20,874 | 14,914 | 11,808 | 6,922 | 5,553 | 2,576 | 1,354 | 1,230 |
Change in fair value of management and incentive units | ||||||||
- | - | - | - | - | - | - | 0 | 0 |
Total expenses | ||||||||
36,559 | 30,599 | 19,474 | 17,066 | 11,882 | 8,881 | 5,224 | 4,514 | 4,461 |
Loss from operations | ||||||||
-18,974 | -15,584 | -9,842 | -11,492 | -9,303 | -6,892 | -4,713 | -3,490 | -4,436 |
Other expense: | ||||||||
Gain on disposal of property and equipment | ||||||||
- | - | - | - | - | - | - | 0 | 0 |
Gain on extinguishment of debt | ||||||||
- | - | - | - | - | - | - | 0 | 0 |
Interest expense, net | ||||||||
-1,033 | -1,461 | -749 | -231 | 9 | -310 | -422 | -564 | -1,044 |
Loss on foreign currency transactions | ||||||||
-350 | -784 | 1,454 | -358 | -507 | -385 | - | - | - |
Penalties associated with non-registration of Series A Preferred Stock | ||||||||
- | - | - | - | - | - | - | 0 | 0 |
Change in warrant liability | ||||||||
- | - | - | - | - | 2,118 | 0 | - | - |
Total other expense, net | ||||||||
-1,384 | -2,245 | 705 | -589 | -497 | -2,814 | -422 | -564 | -1,044 |
Loss before benefit from income taxes | ||||||||
-20,358 | -17,830 | -9,137 | -12,082 | -9,801 | -9,707 | -5,136 | -4,055 | -5,481 |
Benefit from income taxes | ||||||||
-1,092 | -619 | -676 | -318 | -324 | -385 | -458 | -391 | 0 |
Dividend, warrant exercise price adjustment | ||||||||
- | - | -335 | 0 | 0 | - | - | - | - |
Preferred stock dividends | ||||||||
- | - | - | - | - | 9,266 | 2,395 | 2,511 | 3,087 |
Net loss attributable to common shareholders | ||||||||
-19,265 | -17,211 | -8,796 | -11,763 | -9,477 | -18,588 | -7,073 | -6,174 | -8,568 |
Basic and diluted net loss per common share | ||||||||
-0.60 | -0.56 | -0.32 | -0.46 | -0.38 | -1.29 | -0.75 | -0.03 | -0.05 |
Weighted average number of shares of common stock outstanding | ||||||||
32,255 | 30,719 | 27,613 | 25,433 | 24,885 | 14,382 | 9,440 | 198,228 | 160,235 |
Net loss | ||||||||
-19,265 | -17,211 | -8,460 | -11,763 | -9,477 | -9,321 | -4,677 | -3,663 | -5,481 |
Comprehensive loss: | ||||||||
Net loss | ||||||||
-19,265 | -17,211 | -8,460 | -11,763 | -9,477 | -9,321 | -4,677 | -3,663 | -5,481 |
Other comprehensive income (loss): | ||||||||
Currency translation adjustment | ||||||||
237 | 649 | -1,259 | 314 | 356 | 283 | -43 | -12 | - |
Currency translation adjustment | ||||||||
- | - | - | - | - | - | - | - | 0 |
Comprehensive loss | ||||||||
-19,027 | -16,562 | -9,720 | -11,449 | -9,120 | -9,037 | -4,721 | -3,676 | -5,481 |
Product | ||||||||
Total revenue | ||||||||
22,765 | 20,252 | 13,381 | - | - | - | - | - | - |
Cyto Sorb Sales | ||||||||
Total revenue | ||||||||
22,545 | 20,143 | 13,254 | - | - | - | - | - | - |
Other Sales | ||||||||
Total revenue | ||||||||
220 | 109 | 126 | - | - | - | - | - | - |
Grant | ||||||||
Total revenue | ||||||||
2,183 | 2,251 | 1,768 | - | - | - | - | - | - |